CD44H expression in reactive mesothelium, pleural mesothelioma and pulmonary adenocarcinoma

Histopathology

Volumn 30, Issue 3, 1997, Pages 260-263

  Attanoos, R L ^a   Webb, R ^b   Gibbs, A R ^b  

^a UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^b LLANDOUGH HOSPITAL   (United Kingdom)

Author keywords

adenocarcinoma; CD44H; mesothelioma

Indexed keywords

HERMES ANTIGEN;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; PLEURA MESOTHELIOMA; PRIORITY JOURNAL;

EID: 0030970198     PISSN: 03090167     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2559.1997.d01-590.x     Document Type: Article

References (20)

1. Skov BG, Lauritzen AF, Hirsch F et al. The histopathological diagnosis of malignant mesothelioma v pulmonary adenocarcinoma: reproducibility of the histological diagnosis. Histopathology 1994: 24; 553-557.
2. Cibas ES, Corson JM, Pinkus GS. The distinction of adenocarci-noma from malignant mesothelioma in cell blocks of effusions: the role of routine mucin histochemistry and immunohistochem-ical assessment of carcinoembronic antigen, keratin proteins, epithelial membrane antigen and milk fat globule-derived antigen. Hum. Pathol. 1987: 18; 67-74.
3. Wagner JC, Munday DE, Harrington JS. Histochemical demonstration of hyaluronic acid in pleural mesotheliomas. J. Path. Bact. 1962: 84; 73-78.
4. Kannerstein M, Churg J, Magner D. Histochemical studies in the diagnosis of mesothelioma. In Bogovski P ed. Biological Effects of Asbestos. Lyons: IARC. 1973; 62-64.
5. Holden J, Churg A. Immunohistochemical staining for keratin and carcinoembronic antigen in the diagnosis of malignant mesothelioma. Am. J. Surg. Pathol, 1984: 8; 277-279.
6. Gibbs AR, Harach R, Wagner JC et al. Comparison of tumour markers in malignant mesothelioma and pulmonary adenocarcinoma. Thorax 1985: 40; 91-95.
7. Sheibani K, Battifora H, Burke JS. Antigenic phenotype of malignant mesotheliomas and pulmonary adenocarcinomas: an immunohistologic analysis demonstrating the value of Leu M1 antigen. Am. J. Pathol. 1986: 123; 212-219.
8. Sheibani K, Shin SS. Kezirian J et al. Ber EP4 antibody as a discriminant in the differential diagnosis of malignant mesothelioma and adenocarcinoma. J. Am. Surg. Pathol. 1991: 15; 779-784.
9. Collins C, Ordonez NG. Schaefer R et al. Thrombomodulin expression in malignant pleural mesothelioma and pulmonary adenocarcinoma. Am. J. Pathol. 1992: 141; 827-833.
10. Delahaye M, Hoogsteden HC, van der Kwast TH. Immunocytochemistry of malignant mesothelioma: OV 632 as a marker of malignant mesothelioma. J. Pathol. 1991: 165; 137-143.
11. Edwards C, Oates J. OV 632 and MOC 31 in the diagnosis of mesothelioma and adenocarcinoma: an assessment of their use in formalin fixed and paraffin wax embedded material. J. Clin. Pathol. 1995: 48; 626-630.
12. Sheibani K, Esteban J. Bailey A et al. Immunopathologic and molecular studies as an aid to the diagnosis of malignant mesothelioma. Hum. Pathol. 1992: 23; 107-116.
13. Attanoos RL, Goddard H, Gibbs AR. Mesothelioma-binding antibodies: thrombomodulin. OV-632 and HBME-1 and their use in the diagnosis of mesothelioma. Histopathology, in press.
14. Aruffo A, Stamenkovic I, Melnick M et al. CD44 is the principal cell surface receptor for hyaluronate. Cell 1990: 61; 1303-1313.
15. Lesley J, Hyman R, Kincade PW. CD 44 and its interactions with extracellular matrix. Adv. Immunol. 1993: 54; 271-335.
16. Stamenkovic I, Amiot M. Pesando JM et al. A lymphocyte molecule implicated in lymph node homing is a member of the cartilage link protein family. Cell 1989: 56; 1057-1062.
17. World Health Organization. Histological Typing of Lung Tumours. 2nd ed. Geneva: WHO 1981; 21-32.
18. Azumi N, Underhill CB, Kagan E et al. A novel biotinylated probe specific for hyaluronate. Its diagnostic value in diffuse malignant mesothelioma. Am. J. Surg. Pathol. 1992: 16; 116-121.
19. Penno MB, August JT, Baylin SB et al. Expression of CD44 in human lung tumours. Cancer Res. 1994: 54; 1381-1387.
20. Burnett RA, Beck JS. Howatson SR et al. Observer variability in histopathological reporting of malignant bronchial biopsy specimens. J. Clin. Pathol. 1994: 47; 711-713.